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Methods: We included 2882 participants with mild to moderate AD in seven studies from a
meta-database. We used mixed effects models to estimate the rate of decline in Alzheimer’s disease
Assessment Scale-cognitive (ADAS-Cog) scores among Mini-Mental State Examination (MMSE)
groups.
Findings: Baseline MMSE category was associated with baseline scores and rate of decline on the
ADAS-Cog, adjusting for age and education (both P, .001). Greater baseline cognitive impairment
was associated with more rapid progression.
Interpretations: Although we found significant differences in rate of decline, most differences
between individuals were from baseline ADAS-Cog values. Since enrichment based on MMSE
would reduce the recruitment pool while adding only slightly to detecting differences in rate of
progression, it is not advised.
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Given the lack of success in trials of potential disease-
modifying and symptomatic agents for Alzheimer’s disease
(AD), experts have recommended enriching trials with
groups that are more likely to respond [1]. Post hoc analyses
from some AD clinical trials have shown more rapid
progression of diseasewith more severe baseline impairment
[2], suggesting the possibility of a differential response
to treatment. This has led to recommendations foruthor. Tel.: 11-323-442-7600; Fax: 11-205-934-
chneid@usc.edu
16/j.trci.2015.03.001
e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).selecting trials participants based on initial severity, which
is usually based on scores on the Mini-Mental State
Examination (MMSE) [3] or the Alzheimer’s Disease
Assessment Scale-cognitive (ADAS-Cog) [4]. However,
the results of post hoc analyses have not been consistent
across trials [5].
Recently, Ito and colleagues developed a mathematical
model of disease progression in AD based on meta-
analysis of summary data from the literature [6] and
individual-level data from the Alzheimer’s Disease Neuroi-
maging Initiative (ADNI) [7], with this model receiving
approval from the Food and Drug Administration and the
European Medicines Agency for simulating clinical trials.imer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
Placebo-controlled and observational studies included in the analyses
Study (code), dates Design Intervention N
Duration
(months) Minimal severity
Selegiline, vitamin E, 1993–1996 [12] RCT, moderate to severe AD Vitamin E, selegiline 341 24 CDR 2 or greater
Prednisone 1995–1998 [13] RCT, mild to moderate AD Prednisone 138 16 MMSE 13–26
Conjugated estrogens 1995–1999 [14] RCT, mild to moderate AD Conjugated estrogens 120 15 MMSE 12–28
Nonsteroidal anti-inflammatory
1999–2001 [15]
RCT, mild to moderate AD Rofecoxib, naproxen 351 12 MMSE 13–26
Simvastatin (LL) 2003–2008 [16] RCT, mild to moderate AD Simvastatin 406 18 MMSE 12–26
Divalproex 2003–2009 [17] RCT, moderate AD Divalproex 313 24 MMSE 12–20
Vitamins B 2003–2007 [18] RCT, mild to moderate AD B vitamins 409 18 MMSE 14–26
Huperzine 2004–2007 [19] RCT, mild to moderate AD Huperzine A 210 6 MMSE 10–24
Docosahexaenoic acid 2006–2009 [20] RCT, mild to moderate AD Docosahexaenoic acid 402 18 MMSE 14–26
Alzheimer’s Disease Neuroimaging
Initiative (ADNI) 2005–2010 [9]
Observational, AD, MCI, normal None 800 (192 AD,
398 MCI,
229 normal)
36 (AD) MMSE 20–26
Abbreviations: RCT, randomized controlled trial; AD, Alzheimer’s disease; CDR, Clinical Dementia Rating Scale; MMSE, Mini-Mental State Examination;
MCI, mild cognitive impairment.
NOTE. Studies were drawn from the Alzheimer’s Disease Cooperative Study (http://www.adcs.org) and the ADNI (http://adni.loni.ucla.edu) and included
participants with dementia due to AD and baseline MMSE assessments.
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associated with baseline ADAS-Cog scores and the rate of
decline on the ADAS-Cog over time. However, the
implications of enrichment based on MMSE scores were
not investigated using this model.
We empirically tested the potential efficiency of these
recommendations for enrichment based on MMSE scores by
comparing the rate of progression across a broad range of base-
line cognitive severities assessed by the MMSE, using a
recently developed meta-database of studies from the Alz-
heimer’sDiseaseCooperativeStudy (ADCS) [8] andADNI [9].
2. Methods
2.1. Study overview and participants
Participants for the analysis were drawn from a
meta-database consisting of 18 ADCS studies and ADNI,Table 2
Clinical characteristics and ADAS-Cog ratings among participants with dementia
MMSE category 0–10 11–14 15
N (total 5 2808) 122 307 61
Age 2793 70.9 6 8.7 74.1 6 8.9 75
Education, % ,high school 2799 28% (34) 18% (56) 17
Hispanic (%) 2799 4% (5) 7% (20) 6
Married (%) 2808 75% (91) 74% (226) 69
Caucasian (%) 2799 90% (110) 88% (269) 88
Female (%) 2799 65% (79) 65% (200) 60
Assigned to placebo, % 2808 20% (24) 39% (120) 41
ADAS-Cog (SD)
Baseline 2808 47.9 6 8.6 38.1 6 8.0 31
6 months 2165 50.5 6 9.2 40.4 6 8.8 34
12 months 1890 54.8 6 8.2 44.4 6 9.7 36
18 months 1103 55.3 6 8.1 48.0 6 10.0 39
24 months 343 58.0 6 6.9 49.6 6 8.8 41
Abbreviations: ADAS-Cog, Alzheimer’s disease Assessment Scale-Cognitive; A
dard deviation.
NOTE. Summaries are presented as mean (SD) for continuous variables and pe
nificant differences among MMSE categories are highlighted in bold.representing both clinical trials and observational studies
in AD, MCI, and normal individuals (National Institutes of
Health grant R01 AG037561) [10]. Inclusion criteria for
the present analysis were (1) diagnosis of dementia due to
AD; (2) completed the MMSE at baseline; (3) completed
at least one assessment on the ADAS-Cog. Of the 19 studies
with 6553 participants, we excluded 6 studies that enrolled
only participants with MCI or normal cognitive function, 1
study that did not collect baseline MMSE data, and 3 studies
that did not collect ADAS-Cog data, leaving 10 studies
meeting these inclusion criteria. Of the 2888 participants
with AD in these 10 studies, 6 were excluded due to missing
data, yielding a total of 2882 participants for analysis. All di-
agnoses were based on National Institute on Neurological
Disorders and Stroke - Alzheimer’s Disease and Related
Disorders Association (NINDS-ARDRA) criteria [11],
with the additional requirement of a minimal severity baseddue to AD based on MMSE category status
–18 19–22 23–26 27–30 P value
0 884 829 56
.6 6 8.2 76.1 6 8.2 74.7 6 7.6 73.2 6 8.8 ,.001
% (105) 14% (125) 9% (74) 7% (4) ,.001
% (34) 4% (37) 3% (27) 4% (2) .17
% (420) 67% (593) 77% (636) 77% (43) ,.001
% (537) 92% (815) 91% (752) 93% (52) .059
% (367) 61% (536) 51% (423) 59% (33) ,.001
% (249) 46% (411) 48% (398) 54% (30) ,.001
.2 6 7.6 23.4 6 6.8 17.2 6 5.7 13.5 6 4.5 ,.001
.1 6 8.6 25.5 6 7.8 18.6 6 6.8 14.7 6 5.3 ,.001
.9 6 10.0 27.8 6 8.8 20.2 6 7.6 17.0 6 6.3 ,.001
.0 6 10.9 29.8 6 10.0 21.9 6 9.0 19.0 6 6.2 ,.001
.7 6 10.9 33.4 6 11.0 24.6 6 10.1 – ,.001
D, Alzheimer’s disease; MMSE, Mini-Mental State Examination; SD, stan-
rcentage (number) for categorical variables. Items showing statistically sig-
Table 3
Mixed effects (random coefficients) model of ADAS-Cog change over time by MMSE category
Unadjusted Adjusted
Estimate Standard error P value Estimate Standard error P value
Intercept 47.87 0.618 ,.001 47.40 1.325 ,.001
Age, yrs – – – 0.001 0.016 .944
Education
Less than HS – – – – – –
HS graduate – – – 0.49 0.388 .203
College graduate – – – 0.66 0.408 .106
Time, yrs 9.96 0.763 ,.001 9.95 0.763 ,.001
MMSE category
0–10 – – – – – –
11–14 29.90 0.730 ,.001 29.97 0.733 ,.001
15–18 216.73 0.677 ,.001 216.80 0.683 ,.001
19–22 224.64 0.659 ,.001 224.74 0.667 ,.001
23–26 230.83 0.661 ,.001 230.96 0.670 ,.001
27–30 234.45 1.095 ,.001 234.59 1.100 ,.001
MMSE category! time
0–10 – – – – – –
11–14 21.82 0.871 .036 21.82 0.871 .037
15–18 22.76 0.810 ,.001 22.75 0.810 ,.001
19–22 24.54 0.793 ,.001 24.53 0.793 ,.001
23–26 26.31 0.793 ,.001 26.30 0.793 ,.001
27–30 26.73 1.130 ,.001 26.72 1.130 ,.001
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-cognitive; HS, high school; MMSE, Mini-Mental State Examination.
NOTE. Estimates for slopes represent annual rates of change. The rate of change for each group would be the sum of the reference estimate (9.96 points/year
for the most severe group) plus the estimate for the interaction, so that negative interaction terms indicate slower progression. Baseline ADAS-Cog scores for all
categories were significantly different from the reference category of 0 to 10. Rates of progression were significantly different for all categories.
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als analyzed could continue using marketed antidementia
drugs if they had been on stable doses before entry.2.2. Measures
Dementia severity was rated using the MMSE, which is a
brief measure of cognition assessing orientation, attention,
concentration, memory, visual construction, and language.
Scores range from 0 to 30 points, with lower scores indi-
cating greater impairment. MMSE scores of approximately
21 to 25 are consistent with mild dementia, 11 to 20 with
moderate, and 0 to 10 with severe, although cutoffs vary
by study [21]. For this analysis, baseline MMSE scores
were broken a priori into categories of 0 to 10, 11 to 14,
15 to 18, 19 to 22, 23 to 26, and 27 to 30 to allow
comparisons among finer degrees of impairment.
The primary outcome measure was the ADAS-Cog, a
standard scale for AD clinical trials that evaluates memory,
reasoning, orientation, praxis, language, and word finding
difficulty. Scores range from 0 to 70 errors, with higher
scores indicating greater impairment. Clinical assessments
were done at 6-month intervals over the duration of each
study (Table 1).
2.3. Statistical analysis
The primary analyses were conducted using a mixed
effects linear model (random coefficients model) [22], whichadjusts for missing data in testing for differences in the
intercepts (baseline scores) and slopes (rate of change) of
the ADAS-Cog between groups defined by MMSE cate-
gories. The mixed effects model was used as it analyzes
data from all participants (rather than just completers) and
minimizes bias, and it has better controls for type I error in
the presence of missing data [23]. Trials with duration less
than 24 months would still be used in the estimation of the
slope parameter by contributing data at the time points
where observations were collected. A model was
constructed with group effect, visit effect, and group by visit
interactions, with age and education as covariates. Thus, for
participant i51; 2; :::; n at visit j51; 2; :::; ni, the model was
ADASi;j 5 agei 1 educationi 1 groupi 1
timei;j 1 groupi ! timei;j 1 εi;j
which includes both fixed effects of time at the group level
and random effects of time at the individual level. An
unstructured covariance matrix was used to model the inde-
pendence of the slope and intercept parameters. Parameters
were estimated using restricted maximum likelihood. The
primary test of interest was the significance of the group
by time interaction, which would indicate that the slopes
differed byMMSE category. Analyses were performed using
version 3.0.3 of the R programming environment [24].
Mixed model analyses were performed using version
3.1-118 of the NLME package for R [25].
Fig. 1. Predicted Alzheimer’s Disease Assessment Scale-cognitive
(ADAS-cog) score by Mini-Mental State Examination (MMSE) category.
Slopes (rate of change) were significantly different across MMSE category
(all P , .05). However, most of the differences in ADAS-Cog scores at the
end of the trial were due to differences in baseline scores, as shown by the
wide separation of groups at month 0.
Table 4
Estimated group means on the ADAS-Cog by MMSE category and follow-
up assessment time
MMSE category 0 months 6 months 12 months 18 months 24 months
0–10 47.87 52.85 57.82 62.80 67.78
11–14 37.97 42.04 46.11 50.17 54.24
15–18 31.14 34.74 38.34 41.94 45.54
19–22 23.23 25.94 28.65 31.36 34.07
23–26 17.04 18.87 20.69 22.52 24.34
27–30 13.42 15.04 16.65 18.27 19.88
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-
cognitive; MMSE, Mini-Mental State Examination.
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Participants with lower baseline MMSE categories
tended to be older, less educated, and more likely to be
female than those in higher categories (Table 2). Baseline
MMSE category was strongly associated with baseline
ADAS-Cog scores (P , .001). This association remained
significant after adjusting for age and education (P , .001;
Table 3 and Fig. 1). The rates of decline on the ADAS-
Cog also showed significant differences overall (P , .001),
although the slope change from one group to the next higher
group was small relative to the differences in baseline scores
(Fig. 1). Participants in lower (more impaired) MMSE
categories at baseline showed greater rates of progression
on the ADAS-Cog than participants in higher categories.
Differences between groups at the conclusion of the
trial reflected both differences in the baseline scores on
the ADAS-Cog and differences in the rate of decline
over the duration of the trial, with the former having a
greater contribution than the latter. For example, the
mean difference in ADAS-Cog scores between the lower
(MMSE 15–18) and higher (MMSE 23–26) end of most
clinical trials after 24 months was 21.2 points (Table 4).
Of this, 14.1 points were due to differences present at
baseline, leaving 7.1 points due to differences in slope
over the trial period.4. Discussion
These analyses support prior observations that participants
in AD clinical trials show different ADAS-Cog outcomesbased on initial severity on the MMSE. However, these
differences at the end of trials are primarily due to differences
in baseline ADAS-Cog scores. Significant differences were
observed in the slopes, or rate of progression, based on initial
MMSE severity, but the magnitude of these changes was
considerably smaller than the difference in baseline
ADAS-cog scores. Notably, individuals with greater baseline
levels of cognitive impairment (as measured by the MMSE)
had greater rates of progression on the ADAS-Cog than
individuals with lesser baseline cognitive impairment. These
results are consistent with the results of the disease
progression models of Ito and colleagues [6,7], although
they did not report individual-level analyses apart
from ADNI.
These findings have significant implications for
recommendations to enrich AD clinical trials based on
initial severity. Enrichment using this criterion would
select individuals with greater severity as being more
likely to progress, which would be consistent with the
larger slopes (and greater potential for slope reduction)
seen in our analysis. However, such an approach runs
counter to current approaches targeting individuals with
lesser severity as having less neuropathology and being
more likely to respond to treatment [26], which would
be consistent with the larger contribution of baseline
ADAS-Cog scores to the end-of-trial score than the
change due to slope differences. These opposing
recommendations highlight the potential limitations with
analysis of observational studies and post hoc failed
therapeutic trials, which cannot give a definitive depiction
of the effects of a successful treatment.
Enrichment based on baseline severity would have
adverse consequences by shrinking the recruitment pool
for a clinical trial, reducing efficiency by requiring a longer
enrollment period, more clinical sites, or increased
recruitment effort, without a clear gain in efficacy by
targeting likely responders or greatly increasing the rates
of decline. As examples of this, we used the meta-database
to examine the placebo arm of a clinical trial restricted to
more severe samples and to less severe samples (Box 1).
Enrichment based on MMSE status had only a small effect
on the annual rate of change of the ADAS-Cog, and at the
expense of excluding a large number of subjects. Enriching
Box 1
Effects of restricting recruitment using baseline cognition as measured
by the Mini-Mental State Examination (MMSE). When enriching for
more severe disease using baseline MMSE, a slightly larger slope
(rate of decline) was observed but offset by a large reduction in the
size of the available sample in the meta-database meeting the MMSE
cutoff. Enrichment for less severe illness resulted in a slightly smaller
slope, as well as a large reduction in size of the available sample. There-
fore restricting the upper range of MMSE scores is more efficient than
restricting the lower range. Annual rate of change represents the slope
of themixed effects model fitted to the samplewith the specified baseline
MMSE range, while sample size is the number of subjects in the meta-
database with the specified baseline MMSE range
Enrichment for more
severe
Enrichment for less
severe
Baseline MMSE Baseline MMSE
12–26 12–22 16–26 20–26
ADAS-Cog annual
rate of change
5.33 6.27 5.01 4.33
Size of available
sample
2587 1767 2160 1505
Duration 12 months 18 months
Abbreviations: MMSE, Mini-Mental State Examination; ADAS-Cog,
Alzheimer’s Disease Assessment Scale.
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resulted in a difference of less than one point per year on
the ADAS-Cog, but reduced the available sample pool by
more than 800 subjects. Enrichment based on less severe
MMSE scores resulted in a slower rate of progression on
the ADAS-Cog compared with unenriched samples. Such
results indicate that investigators should consider
prospectively stratifying trials based on cognitive severity
rather than enriching based on initial cognitive severity
when attempting to improve AD trial design.
Our analysis has several notable strengths, including the
large sample size and the inclusion of a diverse sample of
clinical trials across multiple sites. However, some
limitations must be acknowledged. Our meta-database of
clinical trials spans more than two decades, and secular
changes in the conduct of clinical trials over this time frame
could have affected results. Also, we only examined the
MMSE as a measure of cognitive severity for predicting
progression. More detailed assessment using neuropsycho-
logical testing may be able to identify individuals who will
experience more rapid decline that the MMSE could not.
However, such in-depth testing is usually not conducted until
after the identification of potential participants is completed,
and brief screening measures such as the MMSE are used to
make initial classifications of severity. Any potential benefits
of neuropsychological testing to enrich clinical trials
samples must be balanced against the increased time and
participant burden required in a screening process that
includes such measures.
Although the goal of directing trials of therapies in AD
toward individuals who are more likely to respond is areasonable one, researchers must also consider whether the
exclusion of potential participants not meeting the
enrichment criteria would adversely affect the efficiency of
the trial [27]. The use of baseline cognitive severity, as
measured by the MMSE, serves as a predictor of disease
progression in mild to moderate AD but may not predict
treatment response. As such, further research to demonstrate
its use is needed, and it cannot be recommended for
enriching clinical trials.Acknowledgments
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1. Systematic review: We reviewed existing literature
on the relationship between baseline cognitive
severity in Alzheimer’s disease (AD) clinical trials
and subsequent rate of decline, which would suggest
the former could be used to enrich clinical trials for
individuals more likely to show therapeutic response.
Several previous studies have shown an association
between more severe cognitive impairment and rate
of decline, but there are inconsistencies among these
reports. To provide a more comprehensive picture,
we analyzed data from seven studies in a meta-
database of AD clinical trials and observational
studies.
2. Interpretation: Our results confirm more severe base-
line cognitive impairment is associated with more
rapid progression of AD.
3. Future directions: Our results provide evidence that
more, rather than less severe AD may be likely to
respond to treatment. Clinical trials in AD should
not exclude participants based on the severity of
cognitive impairment, but include the severity as a
moderator of treatment effects in analysis.References
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